中药制剂治疗阿片类稽延性戒断综合征有效性及安全性的系统评价  

A systematic evaluation on the efficacy and safety of TCM preparations on opioid protracted withdrawal syndrome

作　　者：张儒奇 魏超 王一栋 陈登山 于法涛 张雪文 ZHANG Ruqi

机构地区：[1]济宁医学院中西医结合学院,山东济宁272067

出　　处：《中医临床研究》2022年第22期17-22,共6页Clinical Journal Of Chinese Medicine

摘　　要：目的:系统评价中药制剂治疗阿片类稽延性戒断综合征(Prolonged Withdrawal Syndrome,PWS)的有效性及安全性。方法:计算机检索CNKI、VIP、Wanfang Data、CBM和PubMed数据库,检索中药制剂治疗阿片类PWS的随机对照试验研究,检索时限均从建库至2021年11月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果:共纳入9个随机对照试验,包括1 039例患者,Meta分析结果显示:安君宁与常规药物在PWS总体评分、海洛因渴求量表(Heroin Craving Questionnaire,HCQ)评分、匹兹堡睡眠质量指数量表(Pittsburgh Sleep Quality Index,PSQI)评分等方面的差异均无统计学意义(P> 0.05),济泰片在PWS总体评分、汉密尔顿焦虑量表(Hamilton Anxiety Scale,HAMA)评分、HCQ评分等方面的差异也无统计学意义(P> 0.05)。此外,中药制剂与常规治疗的不良反应发生率的差异无统计学意义(P> 0.05)。结论:当前证据表明,安君宁在降低PWS总体评分、HCQ评分、PSQI评分方面与常规治疗无明显差异,且中药制剂不增加不良反应发生率。受纳入研究的数量和质量的限制,上述结论尚待更多高质量的研究予以验证。Objective:To systematically evaluate the efficacy and safety of TCM preparation on opioid protracted withdrawal syndrome(PWS).Methods:In CNKI,VIP,Wanfang Data,CBM and PubMed databases,the literature on randomized controlled trials of the efficacy and safety of TCM preparations on opioid PWS from inception to November 2021 was retrieved by computer to collect related data.Two investigators independently screened the literature,extracted data and assessed the bias risk of the included studies.A metaanalysis was then performed by Revman 5.4 software.Results:A total of 9 RCTs studies involving 1039 cases were included.The results of the meta-analysis showed that there was no statistically significant difference between Anjunning Wan(安君宁丸)and conventional medicine in ameliorating the observation indicators such as the overall PWS score,HCQ score,PSQI score(P>0.05).There was no statistically significant difference between Jitai tablet(济泰片)and conventional therapy in ameliorating the observation indicators such as overall PWS score,HAMA score and HCQ score(P>0.05).In addition,there was no statistically significant difference in the incidence of adverse reactions between TCM preparations and routine treatment(P>0.05).Conclusion:The current evidence shows that there are no significant difference between Anjunning Wan and conventional therapy in reducing the overall PWS score,HCQ score and PSQI score,and the incidence of adverse reactions of TCM preparations is not increased.Due to limited quality and quantity of the included studies,more high-quality studies are needed to verify the above conclusion.

关 键 词：中药制剂 阿片类物质 稽延性戒断综合征 有效性 安全性 

分 类 号：R163[医药卫生—公共卫生与预防医学]